Formation and identification of a degradant in chlorproguanil-dapsone-artesunate (Dacart™) tablets

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 610-613

  Bardsley, Ben ^a   Barry, Samantha J ^a   Drozdz, Malgorzata A ^a   Hancock, Stephen A ^a   Okafo, George N ^a   Szafran, Magdalena M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti malarial drug; Artesunate; Chlorproguanil; Dacart ; Dapsone; Degradation

Indexed keywords

ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; DACART; SUCCINIC ACID; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG DEGRADATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SHELF LIFE; TABLET FORMULATION;

ANTIMALARIALS; ARTEMISININS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DAPSONE; DRUG COMBINATIONS; DRUG STABILITY; DRUG THERAPY, COMBINATION; HOT TEMPERATURE; HUMANS; HUMIDITY; MAGNETIC RESONANCE SPECTROSCOPY; MALARIA, FALCIPARUM; MASS SPECTROMETRY; PROGUANIL; TABLETS;

EID: 78149496849     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.033     Document Type: Article

References (12)

1. WHO Fact Sheet No. 94, http://www.who.int/mediacentre/factsheets/fs094/en.
2. Schlitzer M. Antimalarial drugs-what is in use and what is in the pipeline. Arch. Pharm. Chem. Life Sci. 2008, 341:149-163.
3. Simpson J.A., Hughes D., Manyando C., Bojang K., Aarons L., Winstanley P., Edwards G., Watkins W.A., Ward S. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br. J. Clin. Pharmacol. 2006, 61:289-300.
4. Martinelli A., Moreira R., Cravo P.V.L. Malaria combination therapies: advantages and shortcomings. Mini-Rev. Med. Chem. 2008, 8:201-212.
5. WHO Facts on ACTS, January 2006 update, http://www.rollbackmalaria.org/cmc_upload/0/000/015/364/RBMInfosheet_9.pdf.
6. Rich S.M., Leendertz F.H., Xu G., LeBreton M., Djoko C.F., Aminake M.N., Takang E.E., Diffo J.L.D., Pike B.L., Rosenthal B.M., Formenty P., Boesch C., Ayala F.J., Wolfe N.D. The origin of malignant malaria. Proc. Natl. Acad. Sci. 2009, 106:14902-14907.
7. Wells T.N.C., Alonso P.L., Gutteridge W.E. New medicines to improve control and contribute to the eradication of malaria. Nature Rev. Drug Disc. 2009, 8:879-891.
8. Stability testing of active substances and pharmaceutical products, Regional Guideline for the WHO Eastern Mediterranean Region, Draft 2, 0, 19 April 2006.
9. Dietz R., Feilner K., Gerst F., Grimm W. Drug stability testing-classification of countries according to climatic zone. Drugs Made Ger. 1993, 36:99-103.
10. Haynes R.K., Chan H.-W., Lung C.-M., Ng N.-C., Wong H.-N., Shek L.Y., Williams I.D., Cartwright A., Gomes M.F. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem 2007, 2:1448-1463.
11. Tiono A.B., Dicko A., Ndububa D.A., Agbenyega T., Pitmang S., Awobusuyi J., Pamba A., Duparc S., Goh L.-E., Harrell E., Carter N., Ward S.A., Greenwood B., Winstanley P.A. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized double-blind, Phase III trial in African children, adolescents, and adults with uncomplicated plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2009, 81:969-978.
12. Premji Z., Umeh R.E., Owusu-Agyei S., Esamai F., Ezedinachi E.U., Oguche S., Borrmann S., Sowunmi A., Duparc S., Kirby P.L., Pamba A., Kellam L., Guiguemdé R., Greenwood B., Ward S.A., Winstanley P.A. Chlorpgroguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized double-blind Phase III trial in African children and adolescents with uncomplicated plasmodium falciparum malaria. PLoS ONE 2009, 4(8):e6682. 10.1371/journal.pone.0006682.